Xenoport Inc. (XNPT) announced favorable preliminary results from a Phase 1 clinical trial after the close Thursday. The study was designed to assess the pharmacokinetics, safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. The stock is now up 0.33 on 6K shares.
Xenoport declined during the first 2 hours of trade Thursday and finished down by 0.15 at $11.15. The stock closed near the middle of a 2 1/2 week range.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.